On November 16, 2017 Genmab A/S (Nasdaq Copenhagen: GEN) reported that it has achieved a USD 50 million sales volume milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech, Inc (Press release, Genmab, NOV 17, 2017, View Source [SID1234522123]). The milestone was triggered by confirmation by Janssen that sales of DARZALEX reached USD 1 billion in a calendar year. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize DARZALEX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to be pleased with the rapid uptake seen with DARZALEX since its initial launch and approval and are excited to have reached the USD 1 billion sales milestone," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The milestone was included in Genmab’s 2017 financial guidance published on November 14, 2017.